{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
theophylline
to a specific field?
Status:
Possibly Marketed Outside US
Source:
Duolip forte by Ludwig Merckle|Co KG chem.-pharm. Fabrik
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Theofibrate (Etofylline clofibrate, trade name Duolip) is the clofibric acid ester of theophylline, used for the treatment of hyperlipoproteinaemia with elevated triglycerides and cholesterol. The low dose of Etophylline clofibrate (750mg) has a similar lipid-lowering effect as pure clofibrate (1500mg), probably due to a synergistic hypolipidemic effect with theophylline, which has no lipid-lowering effect per se. Secondly, etophylline clofibrate substantially decreases platelet aggregability and plasma viscosity, properties which may be desirable in the prevention of coronary heart disease (CHD). Finally, etophylline clofibrate is clearly a less potent inducer of peroxisomal proliferation in the rat liver than clofibrate, bezafibrate or fenofibrate. Theofibrate increases lipoprotein lipase activity to promote the conversion of Very low-density lipoprotein (VLDL) to Low-density lipoprotein (LDL), and hence reduce the level of VLDL.
Status:
Possibly Marketed Outside US
Source:
ETOFYLLINE by Lespagnol, A. et al.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Etofylline [7-(2-hydroxyethyl)theophylline] is a N-7-substituted derivative of theophylline, a smooth muscle relaxant. Etofylline is used to relieve bronchoconstriction. It may act as a phosphodiesterase inhibitor and adenosine receptor antagonist.
Status:
Investigational
Source:
NCT03333824: Phase 1 Interventional Completed Solid Tumours
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03830736: Not Applicable Interventional Completed Postprandial Glucose Regulation
(2019)
Source URL:
Class:
PROTEIN
